NCT07102381 2026-03-12
EmpowHER 208
Jazz Pharmaceuticals
Phase 2 Recruiting
Clinical Trials
25 trialsNCT00781612 2025-12-24
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
Genentech, Inc.
Phase 2 Active not recruiting
NCT05954143 2025-11-20
Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
Bolt Biotherapeutics, Inc.
Phase 2 Terminated
NCT06178159 2025-10-01
DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer
RemeGen Co., Ltd.
Phase 2 Recruiting
NCT07116824 2025-08-12
HB1801 Combined Treatment of HER2-positive Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2 Not yet recruiting
NCT06445400 2025-08-03
A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2 Recruiting
NCT02091141 2024-07-23
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
Genentech, Inc.
Phase 2 Completed
NCT03272477 2024-04-17
TP-II
Palleos Healthcare GmbH
Phase 2 Completed
NCT02229149 2022-12-02
Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer
US Oncology Research
Phase 2 Terminated
NCT02536339 2021-12-07
A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy
Genentech, Inc.
Phase 2 Completed
NCT01491737 2020-10-28
PERTAIN
Hoffmann-La Roche
Phase 2 Completed
NCT01461057 2018-08-09
JOSHUA
Hoffmann-La Roche
Phase 2 Completed
NCT00545688 2017-08-15
A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.
Hoffmann-La Roche
Phase 2 Completed
NCT00058552 2017-03-08
A Study to Evaluate the Effect of HER2 Activation on rhuMAb 2C4 (Pertuzumab) in Subjects With Advanced Ovarian Cancer
Genentech, Inc.
Phase 2 Completed
NCT00976989 2017-02-06
A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT01565083 2016-11-22
VELVET
Hoffmann-La Roche
Phase 2 Completed
NCT01674062 2016-08-22
A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) in Participants With Metastatic Breast Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT02480010 2015-09-18
A Study of Pertuzumab in Participants With Prostate Cancer
Hoffmann-La Roche
Phase 2 Terminated
NCT02491892 2015-08-25
A Study of Pertuzumab in Participants With Metastatic Breast Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT00063154 2015-07-07
Safety and Effect of Pertuzumab in Patients With Advanced Non-Small Cell Lung Cancer, Which Has Progressed After Prior Chemotherapy
Genentech, Inc.
Phase 2 Completed
NCT00058539 2015-06-23
Safety and Efficacy Study of Pertuzumab to Treat Castration-Resistant Prostate Cancer
Genentech, Inc.
Phase 2 Completed
NCT00096993 2015-06-10
A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Genentech, Inc.
Phase 2 Completed
NCT02004093 2014-12-04
A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT00943670 2013-05-27
Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression
Genentech, Inc.
Phase 2 Completed
NCT00855894 2013-05-21
PENGUIN
Genentech, Inc.
Phase 2 Completed